Scarica l'app Stockscreener
67.12
3.02%
-2.09
Dopo l'orario di chiusura:
67.10
-0.02
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
(HALO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Halozyme Therapeutics Earnings: What To Look For From HALO - Yahoo Finance UK
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK - Insider Monkey
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 - Moomoo
HALO Stock Jumps After Earnings Beat And $1B Buyback - StocksToTrade
Halozyme jumps as Q1 results, $1B buyback authorization, and new partnership updates lift sentiment - Quiver Quantitative
Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley - marketscreener.com
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and … - AlphaStreet
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Halozyme stock rating on strong Q1 results By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating - marketscreener.com
Citizens reiterates Halozyme stock rating on strong Q1 results - Investing.com
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlight - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
HALO Maintained by Morgan Stanley -- Price Target Lowered to $93 - GuruFocus
Halozyme Therapeutics (HALO) Reports Strong Q1 2026 Earnings and Growth Outlook - GuruFocus
Halozyme Therapeutics Q1 Earnings Call Highlights - Inkl
Halozyme Q1 2026 slides: revenue surges 42%, $1B buyback unveiled - Investing.com Canada
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Halozyme (HALO) Q1 2026 Earnings Transcript - AOL.com
Halozyme Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HALO) 2026-05-11 - Seeking Alpha
Halozyme Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook - Insider Monkey
HALO Posts Strong Q1 Results and Announces $1B Share Repurchase Program - GuruFocus
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises By Investing.com - Investing.com Nigeria
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance - MarketBeat
MSN Money - MSN
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback - ChartMill
Halozyme beats Q1 expectations, but guidance trails estimates By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Releases Q1 2026 Earnings: Revenue Beats Estimates but EPS Miss - Quiver Quantitative
HALOZYME THERAPEUTICS ($HALO) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Halozyme Therapeutics Inc Earnings Call Transcript - GuruFocus
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):